Preliminary association of circulating tumor cells (CTCs) pre- and post-AdHER2 dendritic cell vaccination with overall survival in patients with metastatic HER2+ solid tumors

Documenti analoghi

• Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
  di: Roßwag, Sven, et al.
  Pubblicazione: (2021)
• Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer
  di: Mego, Michal, et al.
  Pubblicazione: (2016)
• Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity
  di: Wang, Lei, et al.
  Pubblicazione: (2020)
• HER-2 Pulsed Dendritic Cell Vaccine Can Eliminate HER-2 Expression and Impact DCIS
  di: Sharma, Anupama, et al.
  Pubblicazione: (2012)
• Induction of a T helper cell response against the tumor-associated antigen HER2 using monocyte-derived dendritic cells
  di: Metzger, J., et al.
  Pubblicazione: (2002)